HotSpot Therapeutics, Inc., a Boston-based biotechnology company, announced on Wednesday that it is presenting its initial clinical data from the monotherapy dose-escalation portion of the Phase one study of HST-1011 in a Proffered Paper oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024, scheduled from 13 September to 17 September 2024, in Barcelona, Spain.
HST-1011 is an oral and selective inhibitor of Casitas B-lineage lymphoma proto-oncogene (CBL-B).
The clinical data is being revealed with a focus on safety, exposure, and pharmacodynamic measures.
AngioDynamics launches international study to evaluate NanoKnife System for prostate cancer
Reponex Pharmaceuticals granted Japanese patent for colorectal cancer treatment
Inify Laboratories expands to UK, enters gastrointestinal diagnostics
TC BioPharm agrees research planning collaboration to develop Monkeypox treatment
Adcentrx Therapeutics' ADRX-0405 IND application approved by US FDA
Avacta Group partners with Tempus to enhance AI-driven oncology drug development
Novartis receives positive CHMP opinion for Kisqali
OncoZenge partners with Pharmanovia for exclusive BupiZenge commercialization in EMENA regions
SHINE Technologies collaboration could result in new kidney and prostate cancer treatments
Shenzhen Chipscreen Biosciences' IND application for CS231295 tablets accepted in China
Sanofi and Orano partner to advance radioligand therapies
RaySearch secures RayStation orders from French cancer centers under Unicancer agreement
HUTCHMED's TAGRISSO plus ORPATHYS shows promise in lung cancer treatment